Current challenges and controversies in drug-induced liver injury

Drug Safety

Volumn 35, Issue 12, 2012, Pages 1099-1117

  Corsini, Alberto ^a   Ganey, Patricia ^b   Ju, Cynthia ^c   Kaplowitz, Neil ^d   Pessayre, Dominique ^e   Roth, Robert ^b   Watkins, Paul B ^f   Albassam, Mudher ^g   Liu, Baolian ^g   Stancic, Saray ^g   Suter, Laura ^g   Bortolini, Michele ^g  

^a UNIVERSITY OF MILAN   (Italy)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e INSERM   (France)

^f Hamner University of North Carolina   (United States)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Biomarkers; Liver disorders; Liver injury; Postmarketing surveillance

Indexed keywords

5' NUCLEOTIDASE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMIODARONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; ARYLDIALKYLPHOSPHATASE 1; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; BIOLOGICAL MARKER; CLUSTERIN; DICLOFENAC; FIALURIDINE; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE DEHYDROGENASE; GLUTATHIONE TRANSFERASE; HALOTHANE; IDITOL DEHYDROGENASE; LACTATE DEHYDROGENASE; MALATE DEHYDROGENASE; MICRORNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PANADIPLON; PARACETAMOL; PURINE NUCLEOSIDE PHOSPHORYLASE; RIBAVIRIN; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID;

ABNORMAL LABORATORY RESULT; CLINICAL DEVELOPMENT PLAN; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG IDENTIFICATION; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; GENOMICS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFLAMMATION; LABORATORY TEST; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MITOCHONDRION; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; STRESS;

BIOLOGICAL MARKERS; DATABASES, FACTUAL; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; RISK FACTORS;

EID: 84868618214     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11632970-000000000-00000     Document Type: Review

References (149)

1. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009; 16 (23): 3041-53
2. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4 (6): 489-99 (Pubitemid 40861991)
3. de Abajo FJ, Montero D, Madurga M, et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58 (1): 71-80 (Pubitemid 38901470)
4. Sgro C, Clinard F,OuazirK, et al. Incidence of drug-induced hepatic injuries: a French population based study. Hepatology 2002; 36 (2): 451-55 (Pubitemid 34810366)
5. Kaplowitz N. Drug-induced liver disorders: introduction and overview. In: Kaplowitz N, DeLeve L, editors. Druginduced liver disease. 2nd ed. New York: Marcel Dekker, 2007: 1-11
6. Verma S, Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009; 58 (11): 1555-64
7. Jain S,KaplowitzN. Clinical considerations of drug-induced hepatotoxicity. In: McQueen CA, editor. Comprehensive toxicology. 2nd ed. New York: Elsevier Science and Technology, 2010: 369-81
8. Shapiro MA, Lewis JH. Causality assessment of druginduced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007; 11 (3): 477-505 (Pubitemid 47302343)
9. Andrade RJ, Robles M, Ulzurrun E, et al. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10 (9): 1467-87
10. Food and Drug Administration. Guidance for industry. Drug-induced liver injury: Premarketing clinical evaluation. 2009 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInforma tion/Guidances/UCM174090.pdf [Accessed 2011 Sept 20]
11. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA 2002; 287 (17): 2273-5 (Pubitemid 34441944)
12. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89 (6): 806-15
13. Roth RA, Ganey PE. Intrinsic versus idiosyncratic druginduced hepatotoxicity: two villains or one? J Pharmacol Exp Ther 2010; 332 (3): 692-7
14. Zimmerman H. Drug-induced liver disease. In: Zimmerman H, editor. Hepatotoxicity, the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 1999: 428-33
15. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513-39
16. Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47 (6): 2003-9 (Pubitemid 351945567)
17. Lammert C, Bjornsson E, Niklasson A, et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51 (2): 615-20
18. Morita M, Akai S, Hosomi H, et al. Drug-induced hepatotoxicity test using gamma-glutamylcysteine synthetase knockdown rat. Toxicol Lett 2009; 189 (2): 159-65
19. Plummer JL, Hall PD, Jenner MA, et al. Hepatic effects of repeated halothane anesthetics in the hypoxic rat model. Anesthesiology 1987; 67 (3): 355-60 (Pubitemid 18077416)
20. Tasduq SA, Kaiser P, Sharma SC, et al. Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: a toxicity profile study. Hepatol Res 2007; 37 (10): 845-53 (Pubitemid 47308227)
21. Bourdi M, Amouzadeh HR, Rushmore TH, et al. Halothane-induced liver injury in outbred guinea pigs: role of trifluoroacetylated protein adducts in animal susceptibility. Chem Res Toxicol 2001; 14 (4): 362-70 (Pubitemid 32367469)
22. Frost L, Mahoney J, Field J, et al. Impaired bile flow and disordered hepatic calcium homeostasis are early features of halothane-induced liver injury in guinea pigs. Hepatology 1996; 23 (1): 80-6 (Pubitemid 26012095)
23. Lind RC, Gandolfi AJ, Hall PM. Glutathione depletion enhances subanesthetic halothane hepatotoxicity in guinea pigs. Anesthesiology 1992; 77 (4): 721-7
24. Lind RC, Gandolfi AJ, Hall PD. Subanesthetic halothane is hepatotoxic in the guinea pig. Anesth Analg 1992; 74 (4): 559-63
25. Lind RC, Gandolfi AJ, Hall PM. A model for fatal halothane hepatitis in the guinea pig. Anesthesiology 1994; 81 (2): 478-87 (Pubitemid 24320640)
26. Lind RC, Gandolfi AJ. Late dimethyl sulfoxide administration provides a protective action against chemically induced injury in both the liver and the kidney. Toxicol Appl Pharmacol 1997; 142 (1): 201-7 (Pubitemid 27051414)
27. Tennant BC, Baldwin BH, Graham LA, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998; 28 (1): 179-91 (Pubitemid 28300000)
28. Kashimshetty R, Desai VG, Kale VM, et al. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2009; 238 (2): 150-9
29. Lee YH, Chung MC, Lin Q, et al. Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2() mice: two-stage oxidative injury. Toxicol Appl Pharmacol 2008; 231 (1): 43-51
30. Ong MM, Wang AS, Leow KY, et al. Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2() mice. Free Radic Biol Med 2006; 40 (3): 420-9 (Pubitemid 43139676)
31. Ong MM, Latchoumycandane C, Boelsterli UA. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol Sci 2007; 97 (1): 205-13 (Pubitemid 47072169)
32. Ulrich RG, Bacon JA, Branstetter DG, et al. Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic. Toxicology 1995; 98 (1-3): 187-98
33. Knapp AC, Todesco L, Beier K, et al. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. J Pharmacol Exp Ther 2008; 324 (2): 568-75 (Pubitemid 351185875)
34. Buchweitz JP, Ganey PE, Bursian SJ, et al. Underlying endotoxemia augments toxic responses to chlorpromazine: is there a relationship to drug idiosyncrasy? J Pharmacol Exp Ther 2002; 300 (2): 460-7
35. Deng X, Stachlewitz RF, Liguori MJ, et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 2006; 319 (3): 1191-9
36. Waring JF, Liguori MJ, Luyendyk JP, et al. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. J Pharmacol Exp Ther 2006; 316 (3): 1080-7 (Pubitemid 43345281)
37. Zou W, Beggs KM, Sparkenbaugh EM, et al. Sulindac metabolism and synergy with tumor necrosis factoralpha in a drug-inflammation interaction model of idiosyncratic liver injury. J Pharmacol Exp Ther 2009; 331 (1): 114-21
38. Zou W, Devi SS, Sparkenbaugh E, et al. Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci 2009; 108 (1): 184-93
39. Lu L, Jones AD, Harkema JR, et al. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci 2012; 125 (1): 126-33
40. Cheng L, You Q, Yin H, et al. Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology 2009; 49 (1): 215-26
41. Shaw PJ, Hopfensperger MJ, Ganey PE, et al. Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci 2007; 100 (1): 259-66 (Pubitemid 47617822)
42. Shaw PJ, Fullerton AM, Scott MA, et al. The role of the hemostatic system in murine liver injury induced by coexposure to lipopolysaccharide and trovafloxacin, a drug with idiosyncratic liability. Toxicol Appl Pharmacol 2009; 236 (3): 293-300
43. Shaw PJ, Beggs KM, Sparkenbaugh EM, et al. Trovafloxacin enhances TNF-induced inflammatory stress and cell death signaling and reduces TNF clearance in a murine model of idiosyncratic hepatotoxicity. Toxicol Sci 2009; 111 (2): 288-301
44. Shaw PJ, Ganey PE, Roth RA. Trovafloxacin enhances the inflammatory response to a Gram-negative or a Grampositive bacterial stimulus, resulting in neutrophildependent liver injury in mice. J Pharmacol Exp Ther 2009; 330 (1): 72-8
45. Shaw PJ, Ditewig AC, Waring JF, et al. Coexposure of mice to trovafloxacin and lipopolysaccharide, a model of idiosyncratic hepatotoxicity, results in a unique gene expression profile and interferon gamma-dependent liver injury. Toxicol Sci 2009; 107 (1): 270-80
46. Shaw PJ, Ganey PE, Roth RA. Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure. J Pharmacol Exp Ther 2009; 328 (1): 62-8
47. Dugan CM, MacDonald AE, Roth RA, et al. A mouse model of severe halothane hepatitis based on human risk factors. J Pharmacol Exp Ther 2010; 333 (2): 364-72
48. You Q, Cheng L, Reilly TP, et al. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006; 44 (6): 1421-31 (Pubitemid 44953648)
49. Shenton JM, Chen J, Uetrecht JP. Animal models of idiosyncratic drug reactions. Chem Biol Interact 2004; 150 (1): 53-70 (Pubitemid 39441295)
50. Caldwell J. The current status of attempts to predict species differences in drug metabolism. Drug Metab Rev 1981; 12 (2): 221-37 (Pubitemid 12072719)
51. Choudhury AI, Chahal S, Bell AR, et al. Species differences in peroxisome proliferation; mechanisms and relevance. Mutat Res 2000; 448 (2): 201-12 (Pubitemid 30139455)
52. Guengerich FP. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997; 106 (3): 161-82 (Pubitemid 27515084)
53. Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006; 2 (6): 875-94 (Pubitemid 44911538)
54. Nebert DW, Dalton TP, Stuart GW, et al. "Gene-swap knock-in" cassette in mice to study allelic differences in human genes. Ann N Y Acad Sci 2000; 919: 148-70
55. Tomlinson ES, Maggs JL, Park BK, et al. Dexamethasone metabolism in vitro: species differences. J Steroid Biochem Mol Biol 1997; 62 (4): 345-52 (Pubitemid 27504766)
56. Gonzalez FJ. Role of gene knockout and transgenic mice in the study of xenobiotic metabolism. Drug Metab Rev 2003; 35 (4): 319-35 (Pubitemid 38018110)
57. Lee SS, Buters JT, Pineau T, et al. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996; 271 (20): 12063-7 (Pubitemid 26157285)
58. Zaher H, Buters JT, Ward JM, et al. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 doublenull mice. Toxicol Appl Pharmacol 1998; 152 (1): 193-9 (Pubitemid 28498688)
59. Cheung C, Yu AM, Ward JM, et al. The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab Dispos 2005; 33 (3): 449-57 (Pubitemid 40279947)
60. Cheung C, Gonzalez FJ. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 2008; 327 (2): 288-99
61. Corchero J, Granvil CP, Akiyama TE, et al. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 2001; 60 (6): 1260-7 (Pubitemid 33144897)
62. Gonzalez FJ, Yu AM. Cytochrome P450 and xenobiotic receptor humanized mice. Annu Rev Pharmacol Toxicol 2006; 46: 41-64 (Pubitemid 43271183)
63. Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001; 33 (4): 981-8 (Pubitemid 32246649)
64. Locke JE, Sun Z, Warren DS, et al. Generation of humanized animal livers using embryoid body-derived stem cell transplant. Ann Surg 2008; 248 (3): 487-93
65. Muruganandan S, Sinal CJ. Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism. Clin Pharmacol Ther 2008; 83 (6): 818-28 (Pubitemid 351704925)
66. van de Steeg E, Stranecky V, Hartmannova H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122 (2): 519-28
67. Begriche K, Massart J, Robin MA, et al. Drug-induced toxicity on mitochondria and lipid metabolism: Mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011; 54 (4): 773-94
68. Lim PL, Liu J, Go ML, et al. The mitochondrial superoxide/thioredoxin-2/ Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol Sci 2008; 101 (2): 341-9
69. Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 2006; 21 (5): 347-56
70. Santos NA, Medina WS, Martins NM, et al. Aromatic antiepileptic drugs and mitochondrial toxicity: effects on mitochondria isolated from rat liver. Toxicol In Vitro 2008; 22 (5): 1143-52
71. Tay VK, Wang AS, Leow KY, et al. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic Biol Med 2005; 39 (7): 949-59
72. Ganey PE, Luyendyk JP, Maddox JF, et al. Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 2004; 150 (1): 35-51 (Pubitemid 39441294)
73. Deng X, Luyendyk JP, Ganey PE, et al. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 2009; 61 (3): 262-82
74. Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010; 118 (1): 7-18
75. Cosgrove BD, King BM, Hasan MA, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009; 237 (3): 317-30
76. Tukov FF, Maddox JF, Amacher DE, et al. Modeling inflammation-drug interactions in vitro: a rat Kupffer cellhepatocyte coculture system. Toxicol In Vitro 2006; 20 (8): 1488-99 (Pubitemid 44537656)
77. Navarro V, Nomenclature Subcommittee Drug Hepatotoxicity Steering Committee. Hepatic adverse event nomenclature document. Jan 2005. Available from URL: http://www.fda.gov/downloads/Drugs/ScienceResearch/../ucm080365.ppt [Accessed 2011 Sept 20]
78. Cai H, Nguyen N, Peterkin V, et al. A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug Metab Dispos 2010; 38 (5): 879-86
79. Zimmerman HJ. Drug-induced liver disease. Drugs 1978; 16 (1): 25-45
80. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11 (2): 272-6
81. Watkins PB. Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 2005; 33 (1): 1-5 (Pubitemid 40216797)
82. Kaplowitz N. Does elevated alkaline phosphatase exclude Hy's Law? Drug-induced liver injury: getting the medicine and science together. Mar 2010 Available from URL: http://www.aasld.org/conferences/educationtraining/Pag es/2010HepatotoxicitySpecialInterestGroupMeeting.aspx [Accessed 2012 Feb 14]
83. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15 (4): 241-3
84. Hunt CM, Papay JI, Edwards RI, et al. Monitoring liver safety in drug development: the GSK experience. Regul Toxicol Pharmacol 2007; 49 (2): 90-100 (Pubitemid 350007855)
85. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123 (4): 1367-84
86. Marrer E, Dieterle F. Impact of biomarker development on drug safety assessment. Toxicol Appl Pharmacol 2010; 243 (2): 167-79
87. Ozer JS, Chetty R, Kenna G, et al. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul Toxicol Pharmacol 2010; 56 (3): 237-46
88. Vanderlinde RE. Review of pyridoxal phosphate and the transaminases in liver disease. Ann Clin Lab Sci 1986; 16 (2): 79-93 (Pubitemid 16154489)
89. Hall RL. Principles of clinical pathology for toxicology studies. In:Wallace Hayes A, editor. Principles and methods of toxicology. 4th ed. Philadelphia: Taylor & Francis, 2001: 1001-38
90. Antoine DJ, Mercer AE, Williams DP, et al. Mechanismbased bioanalysis and biomarkers for hepatic chemical stress. Xenobiotica 2009; 39 (8): 565-77
91. Giffen PS, Pick CR, Price MA, et al. Alpha-glutathione S-transferase in the assessment of hepatotoxicity-its diagnostic utility in comparison with other recognized markers in the Wistar Han rat. Toxicol Pathol 2002; 30 (3): 365-72 (Pubitemid 34556107)
92. Harrison DJ, Kharbanda R, Cunningham DS, et al. Distribution of glutathione S-transferase isoenzymes in human kidney: basis for possible markers of renal injury. J Clin Pathol 1989; 42 (6): 624-8 (Pubitemid 19156433)
93. Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev Clin Lab Sci 1980; 12 (1): 1-58
94. Keeffe EB, Sunderland MC, Gabourel JD. Serum gammaglutamyl transpeptidase activity in patients receiving chronic phenytoin therapy. Dig Dis Sci 1986; 31 (10): 1056-61 (Pubitemid 16025641)
95. Lum G, Gambino SR. Serum gamma-glutamyl transpeptidase activity as an indicator of disease of liver, pancreas, or bone. Clin Chem 1972; 18 (4): 358-62
96. Belfield A, Goldberg DM. Normal ranges and diagnostic value of serum 5'nucleotidase and alkaline phosphatase activities in infancy. Arch Dis Child 1971; 46 (250): 842-6
97. Hill PG, Sammons HG. An assessment of 5'-nucleotidase as a liver-function test. Q J Med 1967; 36 (144): 457-68
98. Seitanidis B, Moss DW. Serum alkaline phosphatase and 5'-nucleotidase levels during normal pregnancy. Clin Chim Acta 1969; 25 (1): 183-4
99. Asada M, Galambos JT. Liver disease, hepatic alcohol dehydrogenase activity, and alcohol metabolism in the human. Gastroenterology 1963; 45: 67-72
100. Wiesner IS, Rawnsley HM, Brooks FP, et al. Sorbitol dehydrogenase in the diagnosis of liver disease. Am J Dig Dis 1965; 10: 147-51
101. Brohult J, Fridell E, Sundblad L. Studies on alkaline phosphatase isoenzymes. Relation to gamma-glutamyltransferase and lactate dehydrogenase isoenzymes. Clin Chim Acta 1977; 76 (2): 205-11 (Pubitemid 8067369)
102. Wroblewski F, Ladue JS. Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med 1956; 91 (4): 569-71
103. Wroblewski F. The clinical significance of transaminase activities of serum. Am J Med 1959; 27: 911-23
104. Jung K, Pergande M, Rej R, et al. Mitochondrial enzymes in human serum: comparative determinations of glutamate dehydrogenase and mitochondrial aspartate aminotransferase in healthy persons and patients with chronic liver diseases. Clin Chem 1985; 31 (2): 239-43 (Pubitemid 16209721)
105. Berk PD, Javitt NB. Hyperbilirubinemia and cholestasis. Am J Med 1978; 64 (2): 311-26 (Pubitemid 8287305)
106. Erlinger S. Secretion of bile. In: Schiff L, Schiff ER, editors. Diseases of the liver. 7th ed. Philadelphia: J. B. Lippincott; 1993: 85-107
107. Friedman LS, Martin P, Munoz SJ. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakin D, Boyer TD, editors. Hepatology: a textbook of liver disease. 3rd ed. Philadelphia: W.B. Saunders; 1996: 791-833
108. Adler M, Hoffmann D, Ellinger-Ziegelbauer H, et al. Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies. Toxicol Lett 2010; 196 (1): 1-11
109. Camps J, Marsillach J, Joven J. Measurement of serum paraoxonase-1 activity in the evaluation of liver function. World J Gastroenterol 2009; 15 (16): 1929-33
110. Ferre N, Camps J, Prats E, et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48 (2): 261-8 (Pubitemid 34107262)
111. Rodrigo L, Hernandez AF, Lopez-Caballero JJ, et al. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 2001; 137 (2): 123-37 (Pubitemid 32825504)
112. Mochida S, Arai M, Ohno A, et al. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats. Hepatology 1999; 29 (5): 1532-40 (Pubitemid 29211057)
113. Misra MK, Khanna AK, Sharma R, et al. Serum malate dehydrogenase (MDH) in portal hypertension-its value as a diagnostic and prognostic indicator. Indian J Med Sci 1991; 45 (2): 31-4
114. Ozer J, Ratner M, Shaw M, et al. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008; 245 (3): 194-205
115. Bu DX, Hemdahl AL, Gabrielsen A, et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 2006; 169 (6): 2245-53 (Pubitemid 351181982)
116. Jayaraman A, Roberts KA, Yoon J, et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1beta: a proteomic analysis. Biotechnol Bioeng 2005; 91 (4): 502-15 (Pubitemid 41099036)
117. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007; 71 (10): 967-70 (Pubitemid 46741985)
118. Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010; 28 (5): 463-9
119. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27 (7): 633-45
120. Zidek N, Hellmann J, Kramer PJ, et al. Acute hepatotoxicity: a predictive model based on focused illumina microarrays. Toxicol Sci 2007; 99 (1): 289-302 (Pubitemid 47250386)
121. Tarantino G, Colao A, Capone D, et al. Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. J Biol RegulHomeost Agents 2011; 25 (1): 47-56
122. Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54 (5): 1767-76
123. Antoine DJ, Williams DP, Kipar A, et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci 2009; 112 (2): 521-31
124. Antoine DJ, Williams DP, Kipar A, et al. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol Med 2010; 16 (11-12): 479-90
125. Amacher DE, Adler R, Herath A, et al. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem 2005; 51 (10): 1796-803 (Pubitemid 41368169)
126. European Medicines Agency. ICH Topic E15. Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. [EMEA/CHMP/ICH/437986/2006] Available from URL: http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002880. pdf [Accessed 2011 Sept 20]
127. Fielden MR, Nie A, McMillian M, et al. Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol Sci 2008; 103 (1): 28-34 (Pubitemid 351524474)
128. Wang K, Zhang S, Marzolf B, et al. Circulating micro-RNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106 (11): 4402-7
129. Laterza OF, Lim L, Garrett-Engele PW, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009; 55 (11): 1977-83
130. Sukata T, Sumida K, Kushida M, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett 2011; 200 (1-2): 46-52
131. Wolf CR, Smith G. Pharmacogenetics. Br Med Bull 1999; 55 (2): 366-86 (Pubitemid 29415548)
132. Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007; 37 (6): 410-5 (Pubitemid 46915785)
133. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64 (12): 1147-61
134. Gupta NK, Lewis JH. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008; 28 (9): 1021-41
135. Hadziyannis SJ, Sette JrH,Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140 (5): 346-55
136. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40 (6): 993-9 (Pubitemid 38670134)
137. Thomas HC. Hepatitis B and D. Medicine 2002; 30: 34-6
138. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44 (1 Suppl.): S132-9 (Pubitemid 43053889)
139. Dieterich DT, Robinson PA, Love J, et al. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38 Suppl. 2: S80-9 (Pubitemid 38328169)
140. Inductivo-Yu I, Bonacini M. Highly active antiretroviral therapy-induced liver injury. Curr Drug Saf 2008; 3 (1): 4-13 (Pubitemid 351227234)
141. Ogedegbe AO, Sulkowski MS. Antiretroviral-associated liver injury. Clin Liver Dis 2003; 7 (2): 475-99 (Pubitemid 36807742)
142. Wit FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186 (1): 23-31 (Pubitemid 34666910)
143. King PD, Perry MC. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am1995; 24 (4): 969-90 (Pubitemid 26107538)
144. McDonald GB, Frieze D. A problem-oriented approach to liver disease in oncology patients. Gut 2008; 57 (7): 987-1003 (Pubitemid 351919535)
145. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy I: hepatocellular injury. Clin Liver Dis 2007; 11 (3): 641-62, viii (Pubitemid 47302346)
146. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006; 15 (4): 213-20
147. Llanos L, Moreu R, Ortin T, et al. The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports. Aliment Pharmacol Ther 2010; 31 (12): 1337-45
148. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338 (13): 916-7
149. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34 (3): 243-52